Department of Pharmacology, School of Pharmacy, University of Granada.
Gene Regulation in Cardiovascular Remodeling and Inflammation Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid.
J Hypertens. 2020 Jul;38(7):1322-1335. doi: 10.1097/HJH.0000000000002368.
To investigate whether toll-like receptor 7 (TLR7) activation induces an increase in blood pressure and vascular damage in wild-type mice treated with the TLR7 agonist imiquimod (IMQ).
Female BALB/c mice (7-9 week old) were randomly assigned to two experimental groups: an untreated control group and a group treated topically with IMQ (IMQ-treated) for 4 or 8 weeks. A group of IMQ-treated mice that take a combination of the antioxidants tempol and apocynin, and another treated IL-17-neutralizing antibody were also performed.
TLR7 activation gradually increased blood pressure, associated with elevated plasma levels of anti-dsDNA autoantibodies, splenomegaly, hepatomegaly, and severe expansion of splenic immune cells with an imbalance between proinflammatory T cells and regulatory T cells. TLR7 activation induced a marked vascular remodeling in mesenteric arteries characterized by an increased media--lumen ratio (≈40%), and an impaired endothelium-dependent vasorelaxation in aortas from wild-type mice after 8 weeks of treatment. In addition, an increased ROS production, as a result of the upregulation of NADPH oxidase subunits, and an enhanced vascular inflammation were found in aortas from IMQ-treated mice. These functional and structural vascular alterations induced by IMQ were improved by antioxidant treatment. Anti-IL-17 treatment reduced blood pressure and improved endothelial dysfunction in IMQ-treated mice.
Our results demonstrate that TLR7 activation induces the development of hypertension and vascular damage in BALB/c mice, and further underscore the increased vascular inflammation and oxidative stress, mediated in part by IL-17, as key factors contributing to cardiovascular complications in this TLR7-driven lupus autoimmunity model.
研究 Toll 样受体 7(TLR7)激活是否会导致野生型小鼠在接受 TLR7 激动剂咪喹莫特(IMQ)治疗后血压升高和血管损伤。
将 7-9 周龄雌性 BALB/c 小鼠随机分为两组:未经处理的对照组和接受 IMQ(IMQ 处理)治疗 4 或 8 周的组。还对接受抗氧化剂替米洛尔和阿朴肉桂酸组合治疗和另一种接受白细胞介素 17 中和抗体治疗的 IMQ 处理的小鼠进行了治疗。
TLR7 激活逐渐升高血压,同时伴有抗 dsDNA 自身抗体的血浆水平升高、脾肿大、肝肿大以及脾免疫细胞的严重扩张,其中促炎 T 细胞和调节性 T 细胞之间失衡。TLR7 激活诱导肠系膜动脉明显的血管重塑,其特征为中膜-腔比(≈40%)增加,以及野生型小鼠主动脉内皮依赖性血管舒张功能受损,治疗 8 周后。此外,还发现 IMQ 处理的小鼠主动脉中 ROS 产生增加,这是由于 NADPH 氧化酶亚基的上调,以及血管炎症增强。抗氧化治疗改善了 IMQ 引起的这些功能和结构血管改变。抗白细胞介素 17 治疗可降低血压并改善 IMQ 处理小鼠的内皮功能障碍。
我们的结果表明,TLR7 激活可诱导 BALB/c 小鼠发生高血压和血管损伤,并且进一步强调血管炎症和氧化应激的增加,部分由白细胞介素 17 介导,是这种 TLR7 驱动的狼疮自身免疫模型中心血管并发症的关键因素。